RESP301 was under investigation in clinical trials for various conditions. It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults... Additionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary complications in surgical patients at risk of...
- Mechanism
- Curator reviewed
RESP301 is a proprietary liquid inhaled Nitric Oxide generator. By delivering localized and sustained NO release in patient airways, RESP301 exerts mutliple effects including: antiviral mechanisms, prevention of SARS-CoV2 adhesion to ACE2 receptors, and downregulation of host cell metabolism and viral replication. In June 2020, Imperial College in London (with sponsor Thirty Respiratory Limited) announced the enrollment of COVID-19 patients in a trial exploring RESP301 efficacy (NCT04460183).
- Code names
- RESP301
What you can answer from here — as of July 08, 2026
Which companies are running trials of RESP301, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account